OTTAWA (dpa-AFX) - Endo International plc (ENDP, ENDP.TO) announced its operating company, Par Pharma, has begun shipping mycophenolate mofetil hydrochloride for injection, which is the generic version of Roche's CellCept. Mycophenolate mofetil hydrochloride for injection is packaged in cartons of four 500 mg single dose vials.
Endo International noted that, according to IMS Health data, U.S. sales of injectable CellCept were approximately $42 million for the 12 months ended October 31, 2016.
Copyright RTT News/dpa-AFX